Bayer Australia Limited has told
the TGA that it will no longer claim
that “Berocca Performance” has
been clinically trialled.
According to the TGA website,
Bayer was responding to a 2010
complaint about the product, with
the company advising that it “has
complied with and will continue
to comply with the regulation 48
decision by the delegate of the
Minister of Health on 15 July 2013”.
Bayer said it has withdrawn
any representations that Berocca
Performance has been clinically
trialled and demonstrated to
improve concentration and reduce
tiredness, and will not use such
representations in any other
advertisement.The above article was sent to subscribers in Pharmacy Daily's issue from 26 Nov 13 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 26 Nov 13
MONTU Group, its subsidiary Alternaleaf Pty Ltd, and their common director Christopher Strauch are facing legal action by the Therapeutic Goods Administration (TGA) in the Federal Court of Australia for alleged unlawful advertising on the effectiveness of their medicinal cannabis products.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.